Ionis Lowers TRYNGOLZA Revenue Guidance and Delays Cash Flow Breakeven to 2029
During its third-quarter 2026 earnings call, Ionis Pharmaceuticals (IONS) reported a slowdown in the commercial launch of TRYNGOLZA, lowering its full-year revenue guidance for the drug to approximately $50 million. Management attributed this shift to a more gradual adoption rate by physicians treating severe hypertriglyceridemia. Despite the setback with TRYNGOLZA, the company saw strong momentum from DAWNZERA, which recorded third-quarter sales of $37 million, a 40% increase. However, unfavorable Phase III clinical trial results in two partnered programs have forced Ionis to push its target for achieving positive cash flow from 2028 back to 2029. The company maintains a strong liquidity position with $1.9 billion in cash and investments.
Tickers: $IONS
Topics: biotechnology earnings report product sales revenue guidance